Business
J&J request for injunction against Amgen is denied
01:00 AM EST on Thursday, November 23, 2006
PHILADELPHIA — A federal judge has denied Johnson & Johnson’s request for a preliminary injunction barring Amgen Inc. from offering discounts on certain drugs to treat side effects of chemotherapy, which J&J blames for declining sales of its anemia drug.
But J&J, of New Brunswick, N.J., said yesterday it still plans to pursue a full trial in the case. J&J argues Amgen’s discounts have hurt sales of Procrit, which treats chemotherapy-related anemia in cancer patients.
J&J has licensed Procrit from Amgen since the 1980s. Amgen sells the same drug under the brand Epogen, but under an agreement with J&J, Amgen only sells Epogen to treat anemia in kidney-dialysis patients, while J&J sells it in non-dialysis settings.
Amgen, with headquarters in Thousand Oaks, Calif., and a manufacturing plant in West Greenwich, also sells a newer drug, Aranesp, to treat anemia in both dialysis and chemotherapy patients, thus competing directly with J&J’s Procrit in chemotherapy settings.
To spur sales, Amgen offers cancer clinics discounts if they purchase certain amounts of Aranesp and two other Amgen chemotherapy-related drugs, Neupogen and Neulasta, which are designed to boost white blood cell counts and ward off infections. Partly as a result, Aranesp sales have taken off and gained market share from Procrit, rising 27 percent to $1.1 billion for the third quarter.
J&J sales of Procrit and Eprex — the brand name it’s sold under in Europe — fell 5.3 percent to $2.4 billion for the third quarter.
| Green eggs, no ham | |
| The best cup of coffee: It's all about the roast | |
| Sweeping views and luxurious lifestyle at The Tower at Carnegie Abbey in Portsmouth |
|
More business stories
Most Viewed Yesterday
Pedroia misses game to be with pregnant wife
Imprisoned for murder, ex-Providence police officer will still collect disability pension
Providence woman slain, boyfriend arrested in N.Y.
Most active surveys
React to proposed toll changes on the Pell, Mount Hope bridges
Tell us your poison ivy stories.
Why do you think Sarah Palin is prematurely stepping down as Alaska's governor?
Most e-mailed in the last 24 hours
Reader Reaction










You must be logged in to contribute. Log in | Register Now!
You are logged in as screenname | Log Out
You are logged in, but do not have a "screen" name. Create a Screen Name